Announcements Trials
Browse Landscape

Phase

Phase 1 31Phase 2 28Phase 1/2 16Phase 3 3Phase NA 2Phase 2/3 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 9Myeloid 4Lymphoid 2Classical hematology 2

Conditions

Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Cyclophosphamide 26Rituximab 17Etoposide 16Methotrexate 15Dexamethasone 15Cytarabine 15Vincristine 14Prednisone 11Doxorubicin 11Radiotherapy 10blinatumomab 8fludarabine 7Mercaptopurine 7Filgrastim 7Daunorubicin 7Asparaginase 7pegaspargase 6Granulocyte Colony-Stimulating Factor 6Methylprednisolone 5Drug Therapy 5Dasatinib 5venetoclax 4prednylidene 4etoposide phosphate 4deltacortene 4Trimethoprim, Sulfamethoxazole Drug Combination 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Busulfan 4Bendamustine Hydrochloride 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Azacitidine × Lymphoid × Clear all
NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
422 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT07389616 2026-02-05

A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2/3 Recruiting
40 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡